Abstract
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Area Under Curve
-
Azithromycin / adverse effects
-
Azithromycin / pharmacokinetics*
-
Azithromycin / pharmacology
-
Drug Combinations
-
Drug Interactions
-
Drug Therapy, Combination / pharmacokinetics*
-
Drug Therapy, Combination / pharmacology
-
Female
-
HIV Infections / metabolism*
-
Humans
-
Male
-
Rifabutin / adverse effects
-
Rifabutin / pharmacokinetics*
-
Rifabutin / pharmacology
Substances
-
Drug Combinations
-
Rifabutin
-
Azithromycin